Literature DB >> 21913872

Genetic association studies in drug-induced liver injury.

Ann K Daly1, Christopher P Day.   

Abstract

A large number of case-control association studies on genetic susceptibility to drug-induced liver injury, involving both candidate gene and genome-wide association approaches, have now been reported. The strongest associations have been observed for human leukocyte antigen (HLA) class I and II genes and N-acetyltransferase 2 (NAT2). The associations with HLA class I and II genes are drug specific, though some apparently unrelated compounds show genetic associations with the same alleles. The underlying mechanism for the HLA association is likely to involve T-cell responses to either drug-protein adducts or to drug alone, but needs further investigation. The NAT2 association relates to liver injury induced by isoniazid, with most published studies finding an increased risk of injury in slow acetylators lacking NAT2 enzyme activity, presumably because of the accumulation of toxic metabolites. Other associations with genes relevant to drug disposition, innate immunity, oxidative stress, and mitochondrial function have also been reported, though these still need to be confirmed by replication in independent cohorts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21913872     DOI: 10.3109/03602532.2011.605790

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  31 in total

1.  Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

Authors:  Thomas J Urban; David B Goldstein; Paul B Watkins
Journal:  Pharmacogenomics       Date:  2012-05       Impact factor: 2.533

Review 2.  Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology.

Authors:  Barbara L F Kaplan; Jinze Li; John J LaPres; Stephen B Pruett; Peer W F Karmaus
Journal:  Toxicol Sci       Date:  2015-06       Impact factor: 4.849

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

4.  Introduction to mammalian genome special issue: the combined role of genetics and environment relevant to human disease outcomes.

Authors:  Ivan Rusyn; Steven R Kleeberger; Kimberly A McAllister; John E French; Karen L Svenson
Journal:  Mamm Genome       Date:  2018-02       Impact factor: 2.957

Review 5.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

6.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

7.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 8.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

Review 9.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

Review 10.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.